Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers
| Autor: | Vittorio Franciosi, Marzia Capelletti, Nicoletta Campanini, Guido Rindi, Alessandro Marchioni, Elena Spiritelli, Giulio Rossi, Cecilia Bozzetti, Roberta Camisa, Giuseppe De Palma, Costanza Lagrasta, Andrea Ardizzoni, Luca Boni, Giuliana Sartori, Marcello Tiseo |
|---|---|
| Přispěvatelé: | Tiseo M, Rossi G, Capelletti M, Sartori G, Spiritelli E, Marchioni A, Bozzetti C, De Palma G, Lagrasta C, Campanini N, Camisa R, Boni L, Franciosi V, Rindi G, Ardizzoni A |
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male Pulmonary and Respiratory Medicine Oncology Cancer Research medicine.medical_specialty Lung Neoplasms Receptor ErbB-2 Gene Dosage non-small cell lung cancer (NSCLC) Antineoplastic Agents NSCLC Gefitinib EGFR gene mutation EGFR FISH EGFR gene polymorphism Biological predictive factors Gene mutation EGFR Gene Mutation Gene dosage Gefitinib Carcinoma Non-Small-Cell Lung Internal medicine Biomarkers Tumor medicine Carcinoma Humans Prospective Studies Epidermal growth factor receptor Protein Kinase Inhibitors Aged Aged 80 and over Polymorphism Genetic biology business.industry Cancer Middle Aged Prognosis medicine.disease Introns respiratory tract diseases ErbB Receptors Treatment Outcome Immunology Quinazolines biology.protein Female business medicine.drug |
| Zdroj: | Lung Cancer. 67:355-360 |
| ISSN: | 0169-5002 |
| DOI: | 10.1016/j.lungcan.2009.04.021 |
| Popis: | A number of different clinical characteristics and molecular markers related to epidermal growth factor receptor (EGFR) activation have been reported to singly correlate with therapeutic activity of EGFR tyrosine kinase inhibitors (TKIs) in advanced non-small cell lung cancer (NSCLC). This study was designed to evaluate the predictive value on gefitinib outcomes of a comprehensive panel of molecular parameters in advanced NSCLC patients EGFR and K-ras mutations were detected by direct sequencing on tumor DNA from paraffin embedded samples EGFR and HER2 gene copy number was assessed by FISH EGFR protein expression was quantified by immunohistochemistry. EGFR gene intron 1 polymorphism was assessed on genomic DNA isolated from venous whole blood samples Ninety-one patients were prospectively enrolled and the overall gefitinib response rate was 18 7% (2 complete and 15 partial responses) Sex (p = 0005), non-smoking status (p = 0010). skin toxicity (p = 0020). EGFR gene mutations (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect